AA
ADCT icon

ALPS Advisors’s ADC Therapeutics ADCT Stock Holding History

ALPS Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,571
Closed -$186K – 1023
2022
Q3 		$186K Sell
38,571
-6,992
-15% -$50.6K ﹤0.01% 1006
2022
Q2 		$362K Sell
45,563
-33,282
-42% -$315K ﹤0.01% 678
2022
Q1 		$1.16M Sell
78,845
-9,944
-11% -$158K 0.01% 297
2021
Q4 		$1.79M Sell
88,789
-5,245
-6% -$126K 0.02% 300
2021
Q3 		$2.55M Sell
94,034
-6,322
-6% -$162K 0.02% 246
2021
Q2 		$2.44M Buy
+100,356
New +$2.33M 0.02% 267

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ALPS Advisors's ADCT Position: Q4 2022 in Review

ALPS Advisors sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 38,571 shares — an estimated $186K sold.

ALPS Advisors first reported a position in ADCT in Q2 2021 and held it in 6 quarters. The position peaked at $2.55M in Q3 2021. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

  • ALPS Advisors reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 38,571 ADC Therapeutics shares in Q4 2022, an estimated $186K.
  • ALPS Advisors first reported a position in ADC Therapeutics in Q2 2021 and held it in 6 quarters.
  • ALPS Advisors's ADC Therapeutics position peaked at $2.55M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.